TIGIT Extracellular Domain (huma

Confirm delete?

TIGIT Extracellular Domain (human, recombinant)

Zoom

Cat No: 32081

Proteins - More Proteins

T cell immunoreceptor with Ig and ITIM domains (TIGIT) is a type I transmembrane immune receptor.{54206} It is composed of an N-terminal extracellular immunoglobulin variable (IgV) domain, a transmembrane domain, and a C-terminal cytoplasmic tail that...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Correlated keywords:

extra cellular HEK 293 immuno globulin receptor CD 155 112 226 Tage 4 Grb 2 SHIP 1 PD1 Met 22 VSig 9 Vstm 3 IFN?

Product Overview:
T cell immunoreceptor with Ig and ITIM domains (TIGIT) is a type I transmembrane immune receptor.{54206} It is composed of an N-terminal extracellular immunoglobulin variable (IgV) domain, a transmembrane domain, and a C-terminal cytoplasmic tail that contains an immunoglobulin tail tyrosine-like (ITT-like) phosphorylation motif and an immunoreceptor tyrosine-based inhibition motif (ITIM).{54207} The ITT-like and ITIM motifs are important for the signaling and inhibitory functions of TIGIT.{54206} It is expressed primarily on natural killer (NK) cells but also expressed on activated, memory, and follicular T helper cells, as well as certain regulatory T cells and exhausted T cells. TIGIT is a co-inhibitory molecule that acts in opposition to the co-stimulatory receptor CD226 (Item Nos. 32071
32072), preventing its interaction with their shared ligands, CD155/Tage4 and CD112/nectin-2, on antigen-presenting cells (APCs), infected cells, and tumor cells. TIGIT on NK cells inhibits NK cell-mediated APC cell killing and lysis, as well as APC-induced cytokine release that, in turn, inhibits IFN-γ secretion from NK cells.{52608} On T cells, TIGIT inhibits T cell cytokine production, proliferation, and T cell receptor signaling.{54206} It also associates with the adapter proteins Grb2 and β-arrestin 2 to recruit SHIP1 for inhibition of NK or T cell activation. In addition to its cell extrinsic activities, TIGIT has cell intrinsic activity, binding directly to CD226 to disrupt its function. Anti-TIGIT antibodies delay the growth of tumors, protect against metastasis, and decrease tumor burden in mouse models of cancer with an increased anticancer effect when used in combination with PD-1 inhibitors.{54208} TIGIT-/- mice have reduced tumor growth and increased survival compared to wild-type mice. The expression of TIGIT on immune cells in melanoma and gastric cancer patients is associated with metastasis and shorter overall survival. Cayman's TIGIT Extracellular Domain (human, recombinant) protein can be used for binding assay and ELISA applications. This protein consists of 128 amino acids, has a calculated molecular weight of 14.2 kDa, and a predicted N-terminus of Met22 after signal peptide cleavage. By SDS-PAGE, the apparent molecular mass of the protein is approximately 19 kDa due to glycosylation.

Size	50 µg
Shipping	dry ice
Formulation	Lyophilized from sterile PBS, pH 7.4
Purity	≥90% estimated by SDS-PAGE
Custom Code	3504.00
UNSPSC code	12352204

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.